Molecular Profile Detail

Filtering

Case insensitive filtering will display rows if any text in any cell matches the filter term
Use simple literal full or partial string matches
Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
Click on any column header arrows to sort by that column
Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Filter rows:

Showing 1 to 33 of 33 entries

Molecular Profile	Indication/Tumor Type	Response Type	Relevant Treatment Approaches	Therapy Name	Approval Status	Evidence Type	Efficacy Evidence	References
FLT3 D835Y	acute promyelocytic leukemia	predicted - sensitive		Arsenic trioxide + Cytarabine + Methotrexate + Tretinoin	Case Reports/Case Series	Actionable	In a clinical case study, a patient with acute promyelocytic leukemia harboring FLT3 D835Y demonstrated a complete molecular remission after treatment with Trisenox (arsenic trioxide) and Vesanoid (tretinoin) combined with Cytosar-U (cytarabine) and Methotrexate (PMID: 27626069).	27626069
FLT3 D835Y	acute promyelocytic leukemia	predicted - resistant		Tretinoin	Case Reports/Case Series	Actionable	In a clinical case study, a patient with acute promyelocytic leukemia developed meningeal relapse after maintenance therapy with Vesanoid (tretinoin), which was found to be due to a FLT3 D835Y variant (PMID: 27626069).	27626069
FLT3 D835Y	hematologic cancer	sensitive		Palbociclib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, transformed cells expressing FLT3 D835Y were sensitive to treatment with Ibrance (palbociclib), demonstrating reduced cell viability in culture and tumor growth inhibition in cell line xenograft models (PMID: 30544932).	30544932
FLT3 D835Y	acute myeloid leukemia	predicted - sensitive		LAM-003	Preclinical - Patient cell culture	Actionable	In a preclinical study, patient-derived acute myeloid leukemia cells harboring FLT3 D835Y demonstrated sensitivity to LAM-003 treatment in culture (PMID: 31751472).	31751472
FLT3 D835Y	Advanced Solid Tumor	sensitive	FLT3 Inhibitor	Midostaurin	Preclinical - Cell culture	Actionable	In a preclinical study, treatment with Rydapt (midostaurin) inhibited FLT3 phosphorylation and resulted in decreased proliferation and viability of transformed cells expressing FLT3 D835Y in culture (PMID: 12124173).	12124173
FLT3 D835Y	acute myeloid leukemia	sensitive	FLT3 Inhibitor	E6201	Preclinical - Cell culture	Actionable	In a preclinical study, E6201 induced apoptosis in blast samples derived from acute myeloid leukemia patients harboring FLT3 D835Y in culture (PMID: 26822154).	26822154
FLT3 D835Y	Advanced Solid Tumor	sensitive	FLT3 Inhibitor	MRX-2843	Preclinical - Cell culture	Actionable	In a preclinical study, MRX-2843 inhibited Flt3 signaling, resulted in growth inhibition in Quizartinib (AC220)-resistant transformed cells over expressing FLT3 D835Y in culture (PMID: 27158668).	27158668
FLT3 D835Y	hematologic cancer	sensitive	FLT3 Inhibitor	SKI-G-801	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FLT3 D835Y were sensitive to SKI-G-801 in culture, demonstrating inhibition of cell growth and inhibition of Flt3 autophosphorylation (PMID: 24532805).	24532805
FLT3 D835Y	hematologic cancer	sensitive	FLT3 Inhibitor	CG-806	Preclinical - Cell culture	Actionable	In a preclinical study, CG-806 inhibited proliferation of a cell line expressing FLT3 D835Y in culture (PMID: 35499387).	35499387
FLT3 D835Y	hematologic cancer	sensitive	FLT3 Inhibitor	Crenolanib	Preclinical - Cell culture	Actionable	In a preclinical study, Crenolanib (CP-868596) decreased proliferation of transformed cells expressing FLT3 D835Y in culture (PMID: 30651561).	30651561
FLT3 D835Y	hematologic cancer	sensitive	FLT3 Inhibitor	Crenolanib + Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Crenolanib (CP-868596) and Mekinist (trametinib) synergistically decreased proliferation of transformed cells expressing FLT3 D835Y in culture (PMID: 30651561).	30651561
FLT3 D835Y	hematologic cancer	sensitive	FLT3 Inhibitor	Crenolanib	Preclinical - Cell culture	Actionable	In a preclinical study, Crenolanib inhibited growth of transformed hematologic cells expressing FLT3 D835Y in culture (PMID: 31309543).	31309543
FLT3 D835Y	hematologic cancer	conflicting	FLT3 Inhibitor	Quizartinib	Preclinical - Cell culture	Actionable	In a preclinical study, Vanflyta (quizartinib) inhibited growth of transformed hematologic cells expressing FLT3 D835Y in culture (PMID: 31309543).	31309543
FLT3 D835Y	hematologic cancer	sensitive	FLT3 Inhibitor	Gilteritinib	Preclinical - Cell culture	Actionable	In a preclinical study, Xospata (gilteritinib) inhibited growth of transformed hematologic cells expressing FLT3 D835Y in culture (PMID: 31309543).	31309543
FLT3 D835Y	hematologic cancer	sensitive	FLT3 Inhibitor	Midostaurin	Preclinical - Cell culture	Actionable	In a preclinical study, Rydapt (midostaurin) inhibited growth of transformed hematologic cells expressing FLT3 D835Y in culture (PMID: 31309543).	31309543
FLT3 D835Y	hematologic cancer	resistant	FLT3 Inhibitor	Sorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed hematologic cells expressing FLT3 D835Y were resistant to Nexavar (sorafenib)-induced growth inhibition in culture (PMID: 31309543).	31309543
FLT3 D835Y	hematologic cancer	resistant		Avapritinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed hematologic cells expressing FLT3 D835Y were resistant to Ayvakit (avapritinib)-induced growth inhibition in culture (PMID: 31309543).	31309543
FLT3 D835Y	acute myeloid leukemia	sensitive		Palbociclib	Preclinical - Cell culture	Actionable	In a preclinical study, patient-derived acute myeloid leukemia cells harboring FLT3 D835Y were sensitive to treatment with Ibrance (palbociclib) in culture, demonstrating reduced cell viability and colony formation (PMID: 30544932).	30544932
FLT3 D835Y	hematologic cancer	sensitive		Danusertib + Palbociclib	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Ibrance (palbociclib) and Danusertib (PHA-739358) resulted in a synergistic effect, leading to a greater decrease in cell viability of transformed cells expressing FLT3 D835Y in culture compared to either agent alone (PMID: 30544932).	30544932
FLT3 D835Y	hematologic cancer	sensitive		Alisertib + Palbociclib	Preclinical - Cell culture	Actionable	In a preclinical study, the combination treatment of Ibrance (palbociclib) and Alisertib (MLN8237) resulted in a synergistic effect in transformed cells expressing FLT3 D835Y, demonstrating a greater reduction in cell viability compared to either agent alone (PMID: 30544932).	30544932
FLT3 D835Y	hematologic cancer	sensitive		Everolimus + Palbociclib	Preclinical - Cell culture	Actionable	In a preclinical study, the combination therapy of Ibrance (palbociclib) and Afinitor (everolimus) resulted in a synergistic effect in transformed cells expressing FLT3 D835Y, demonstrating a greater reduced cell viability compared to either agent alone (PMID: 30544932).	30544932
FLT3 D835Y	hematologic cancer	sensitive	FLT3 Inhibitor	Olverembatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Olverembatinib (HQP1351) inhibited growth of transformed cells expressing FLT3 D835Y in culture (PMID: 32247263).	32247263
FLT3 D835Y	hematologic cancer	sensitive		Dubermatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Dubermatinib (TP-0903) inhibited growth of transformed cells expressing FLT3 D835Y in culture (PMID: 33268594).	33268594
FLT3 D835Y	hematologic cancer	sensitive	FLT3 Inhibitor	LT-171-861	Preclinical - Cell culture	Actionable	In a preclinical study, LT-171-861 inhibited cell viability and decreased FLT3 phosphorylation in transformed cells expressing FLT3 D835Y in culture (PMID: 33391463).	33391463
FLT3 D835Y	hematologic cancer	sensitive	FLT3 Inhibitor	Gilteritinib	Preclinical - Cell culture	Actionable	In a preclinical study, Xospata (gilteritinib) resulted in reduced cell viability in transformed cells expressing FLT3 D835Y in culture (PMID: 32040554).	32040554
FLT3 D835Y	hematologic cancer	sensitive	FLT3 Inhibitor	Pacritinib	Preclinical - Cell culture	Actionable	In a preclinical study, Vonjo (pacritinib) inhibited kinase activity and viability in a transformed cell line expressing FLT3 D835Y in culture (PMID: 31102119).	31102119
FLT3 D835Y	hematologic cancer	sensitive	FLT3 Inhibitor	Midostaurin	Preclinical - Cell culture	Actionable	In a preclinical study, Rydapt (midostaurin) inhibited growth of cells expressing FLT3 D835Y in culture (PMID: 38049555).	38049555
FLT3 D835Y	hematologic cancer	resistant	FLT3 Inhibitor	Sorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, a cell line expressing FLT3 D835Y was resistant to Nexavar (sorafenib) in culture (PMID: 38049555).	38049555
FLT3 D835Y	hematologic cancer	sensitive	FLT3 Inhibitor	Gilteritinib	Preclinical - Cell culture	Actionable	In a preclinical study, Xospata (gilteritinib) inhibited viability of cultured cells expressing FLT3 D835Y (PMID: 38231480).	38231480
FLT3 D835Y	hematologic cancer	conflicting	FLT3 Inhibitor	Quizartinib	Preclinical - Cell culture	Actionable	In a preclinical study, cultured cells expressing FLT3 D835Y were resistant to treatment with Vanflyta (quizartinib) (PMID: 38231480).	38231480
FLT3 D835Y	hematologic cancer	sensitive		Foretinib	Preclinical - Cell culture	Actionable	In a preclinical study, Foretinib (GSK1363089) inhibited viability of cultured cells expressing FLT3 D835Y (PMID: 38231480).	38231480
FLT3 D835Y	Advanced Solid Tumor	resistant	FLT3 Inhibitor	Pexidartinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing FLT3 D835Y were resistant to PLX3397 in culture (PMID: 25847190).	25847190
FLT3 D835Y	leukemia	sensitive	FLT3 Inhibitor	E6201	Preclinical	Actionable	In a preclinical study, E6201 inhibited proliferation and induced apoptosis in FLT3 inhibitor-resistant leukemia cell lines over expressing FLT3 D835Y in culture (PMID: 26822154).	26822154

Showing 1 to 33 of 33 entries

Filter rows:

Profile Name	FLT3 D835Y
Gene Variant Detail	FLT3 D835Y (gain of function)
Relevant Treatment Approaches	FLT3 Inhibitor

Molecular Profile Detail

Contact

Filtering

Sorting